Rankings
▼
Calendar
LGND Q4 2023 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
LGND
Ligand Pharmaceuticals Incorporated
$4B
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$28M
+3.9% YoY
Gross Profit
$26M
94.1% margin
Operating Income
-$3M
-11.9% margin
Net Income
$18M
64.7% margin
EPS (Diluted)
$1.03
QoQ Revenue Growth
-14.5%
Cash Flow
Operating Cash Flow
$7M
Free Cash Flow
$7M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$787M
Total Liabilities
$86M
Stockholders' Equity
$701M
Cash & Equivalents
$23M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$28M
$27M
+3.9%
Gross Profit
$26M
$5M
+386.8%
Operating Income
-$3M
$12M
-127.6%
Net Income
$18M
-$17M
+204.0%
Revenue Segments
Royalty
$22M
60%
Material Sales, Captisol, Core
$4M
10%
Material Sales, Captisol
$4M
10%
Royalty, Other
$4M
9%
Contract Revenue
$2M
5%
Milestone
$2M
4%
Service
$352,000
1%
← FY 2023
All Quarters
Q1 2024 →